Physician profile
Egbert A Tan
NPI 1245427111
$3,164.01
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,076 · 2020: $238 · 2021: $740 · 2022: $734 · 2023: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $867.22 | 2019-2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $587.78 | 2020-2023 | Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $436.60 | 2019-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $335.54 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $239.93 | 2021-2023 | |
| Allergan, INC. | $161.36 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $110.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $99.24 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $96.02 | 2019-2023 | Hetlioz, Fanapt |
| Indivior INC. | $75.48 | 2021-2023 | Perseris |
| Corium, LLC | $37.98 | 2023 | Azstarys |
| Almatica Pharma LLC | $37.11 | 2021-2023 | Sertraline Hcl, Loreev Xr |
| Abbvie INC. | $28.27 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.16 | 2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $16.59 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $14.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Egbert Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.